StreetInsider.com News Articles

Alpha Tau signs MOU with Samsung Medical Center for pancreatic cancer trial

Thu, 22 Oct 2026 08:31:27 -0400

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) has signed a memorandum of understanding with Samsung Medical Center (SMC) in Seoul, South Korea, to explore a potential clinical trial of its Alpha DaRT® therapy in pancreatic cancer patients, according to a press release from the company.

Any such trial would be subject to regulatory and ethics committee approvals. Alpha Tau said the potential Korea trial would mark Alpha DaRT's first clinical trial in South Korea and could extend its pancreatic cancer program to six countries across North America, Europe, the Middle East, and Asia.

Pancreatic cancer is South Korea's fourth leading cause of

Alpha Tau signs MOU with Samsung Medical Center for pancreatic cancer trial

Thu, 22 Oct 2026 08:31:27 -0400

Pancreatic cancer is South Korea's fourth leading cause of

Alpha Tau signs MOU with Samsung Medical Center for pancreatic cancer trial

Thu, 22 Oct 2026 08:31:27 -0400

Pancreatic cancer is South Korea's fourth leading cause of

Alpha Tau signs MOU with Samsung Medical Center for pancreatic cancer trial

Thu, 22 Oct 2026 08:31:27 -0400

Pancreatic cancer is South Korea's fourth leading cause of

Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea

Thu, 22 Oct 2026 08:30:00 -0400

- MOU relates to a potential clinical trial in South Korea, Alpha DaRT’s first, at Samsung Medical Center (SMC) in Seoul, ranked fifth in the world and number one in Korea in oncology -

- In Korea, only about one in five pancreatic cancer patients undergo surgery, and the disease’s death rate rose over 6% in 2025, the steepest increase among major cancers -

JERUSALEM, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the

Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea

Thu, 22 Oct 2026 08:30:00 -0400

- MOU relates to a potential clinical trial in South Korea, Alpha DaRT’s first, at Samsung Medical Center (SMC) in Seoul, ranked fifth in the world and number one in Korea in oncology -

- In Korea, only about one in five pancreatic cancer patients undergo surgery, and the disease’s death rate rose over 6% in 2025, the steepest increase among major cancers -

JERUSALEM, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the

Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea

Thu, 22 Oct 2026 08:30:00 -0400

- MOU relates to a potential clinical trial in South Korea, Alpha DaRT’s first, at Samsung Medical Center (SMC) in Seoul, ranked fifth in the world and number one in Korea in oncology -

- In Korea, only about one in five pancreatic cancer patients undergo surgery, and the disease’s death rate rose over 6% in 2025, the steepest increase among major cancers -

JERUSALEM, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the

Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea

Thu, 22 Oct 2026 08:30:00 -0400

- MOU relates to a potential clinical trial in South Korea, Alpha DaRT’s first, at Samsung Medical Center (SMC) in Seoul, ranked fifth in the world and number one in Korea in oncology -

- In Korea, only about one in five pancreatic cancer patients undergo surgery, and the disease’s death rate rose over 6% in 2025, the steepest increase among major cancers -

JERUSALEM, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the

Alpha Tau to Participate in October Investor Conferences

Mon, 05 Oct 2026 09:45:00 -0400

JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that company management will participate in the following investor conferences in October 2026.

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 16:01:00 -0400

- Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial enrollment and to add two additional leading U.S. clinical sites -

- Strategic collaboration with Tolmar to develop and commercialize Alpha DaRT® for prostate cancer in the United States, backed by a $20 million equity investment at a 25% premium, $15 million towards expanded U.S. manufacturing capacity, and up to $161.5 million in development, regulatory and commercial milestone payments for the first indication, as well as future ongoing